MACH-19: Mushrooms and Chinese Herbs for COVID-19
MACH-19 Clinical Trials
Mushroom-based Product for COVID-19 (MACH-19)
clinicaltrials.gov/ct/show/NCT04667247
Chinese Herbal Formula for COVID-19 (MACH-19)
clinicaltrials.gov/ct/show/NCT04939415
RCT of Mushroom-based Natural Product to Enhance Immune Response to COVID-19 Vaccination (MACH-19)
clinicaltrials.gov/ct/show/NCT04951336
About the Research
Top researchers at the University of California have launched a groundbreaking FDA-approved clinical trial to study natural medicine approaches to fighting COVID-19. Data analysis from the study is currently underway and will be released as results become available.
Historic Study of Natural Medicine
Many of our most effective antimicrobials, including penicillin, originate from fungi and mushrooms. Unlike pharmaceutical approaches, nature has continuously interacted with our biological world, giving rise to a broad spectrum of defenses against emerging microbial threats.
MACH-19 (Mushrooms and Chinese Herbs for COVID-19) studies an immune-balancing mycological formula with broad-spectrum antiviral activity, alongside a Chinese herbal formula widely used in Asia.
MACH-19 Seeks to Address COVID-19 Through Multiple Approaches
- Treatment for acute COVID-19 patients to help reduce hospitalizations
- Vaccine adjuvant research to safely enhance vaccine effectiveness, extend immunity, and protect against emerging variants
These natural medicines may offer safe, widely available, and affordable tools to address multiple aspects of the pandemic. The FDA clinical trials are based at UC San Diego with collaborators from UCLA, UC Irvine, and the La Jolla Institute for Immunology.
This work addresses not only the current pandemic but future ones as well, contributing scientifically documented knowledge on the potential of natural medicine.
Watch the broadcast news clip here, or read the news article here .